 BETHESDA, Md., March 16, 2021 PRNewswire -- Northwest Biotherapeutics OTCQB: NWBO NW Bio, a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, today announced that development of the initial production capacity of the Companys Sawston, UK advanced manufacturing facility has been completed and the facility is now in the final stages of preparation for an application for certification by the UK Medicines and Health Products Regulatory Authority MHRA. 